New England District Update MassMEDIC Conference December 1, 2010 Waltham, MA.

Slides:

Advertisements

Similar presentations

FDA Medical Device Update

Advertisements

Medical Device Law. FDA FDA Regulated Devices From the Beginning Hubbard Electrometer Cases Magnetic Healing Cases Original Law Required Proof of Harm.

New FDA Regulations and Fees Impacting Customs Brokers, Freight Forwarders and Imported Food Presented by Russell K. Statman, Esq. Executive Director,

FDA Import Operations Overview Border Port Operations and Enforcement Vince Iacono, Compliance Officer U.S. Food and Drug Administration Southwest Import.

Those Elusive FDA Import Requirements: FSMA, PREDICT & the New FDA October 26, 2011 Sponsored by:

FDA Import Operations Embassy Training Seminar Presented by Carl R. Nielsen Director, Div. of Import Operations & Policy November 7, 2003.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

North Carolina Department of Agriculture and Consumer Services Food and Drug Division 4000 Reedy Creek Road Raleigh, NC Harold McDowell, RS Food.

Funding Opportunities for State, Local, Tribal, and Territorial Retail Food Regulatory Programs Cathy Hosman and Pete Salsbury U.S. Food and Drug Administration.

ALERT: The Basics Food and Drug Administration Center for Food Safety and Applied Nutrition.

Metric, Data and Analysis Biometrics Ricki A. Chase Director, Investigations Branch

Import Controls Phase 2 Workgroup 1.

What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.

Introduction to Regulation

Vernon D. Toelle, Ph.D. Team Leader Pre-Market Compliance and Administrative Actions Team (BIMO Team) Overview of CVM Bioresearch Monitoring.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

MAGI's Clinical Trial Agreements, Budgets & Regulatory Conference FDA Inspections of Investigator Sites Paul Below Clinical Research Consultant P. Below.

FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.

The FDA Landscape AdvaMed September 2008 Judith K. Meritz

Steve Stich Director Safety and Inspection Standard 6 Breakout Session Compliance and Enforcement Program March 12, :00am – 12:00 pm Julie Loera.

FDA Resources and Meetings FDA/EMA Orphan Designation and Grant Workshop Silver Spring, Maryland FDA Campus (White Oak) October 12, 2012 Bill Sutton Deputy.

Are you ready for a recall? Medical Device Regulatory, Reimbursement and Compliance Congress March 28, 2007 Willie R. Bryant, Jr. Consultant Stericycle,

FDA Recalls Risk Communication Advisory Committee David K. Elder Director, Office of Enforcement.

Regulatory Update Ellen Leinfuss SVP, Life Sciences.

Ensuring Quality in Medical Device Clinical Trials

Center for Veterinary Medicine (CVM) RECALLS.  21 CFR 7.40 provides guidance on the policy, procedures, and industry responsibilities for recalls. 

USFDA Canned Food Regulations Thermal Processing Deviations Registration and Process Filing William W. Deckert Jr.

FDA Regulatory review in Minutes: What Product Development Executives Need-to-Know. Specifically, frequent causes of recalls and related areas that investigators.

What is Food Recall A food recall is a voluntary action by a manufacturer or distributor to protect the public from products that may cause health problems.

Food and Drug Administration

Top 10 Medical Device Citations

1 Importation of Medical Devices FDA Chicago District O’Hare Import Resident Post August 26, 2010 Import Entry Review Team Tamara M. Qtami, CSO.

Device Clinical Trials and More… Michael E. Marcarelli, PharmD Director, Division of Bioresearch Monitoring Office of Compliance Center for Devices and.

FDA Science BoardNov 5, CDER Risk-based Site Selection Model: An FDA Risk Management Tool Presentation to FDA Science Board November 5, 2004 by Kara.

Kimberly A. Trautman FDA’s Medical Device Quality System Expert

FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.

Latham & Watkins operates as a limited liability partnership worldwide with affiliated limited liability partnerships conducting the practice in the United.

COMPLIANCE ACTIONS FDA Regulation & Licensure of Whole Blood & Blood Components, Including Source Plasma September 15-16, 2009 Helen Cowley Office of Compliance.

Rules for Supporting Part 803 and Part 806 Decision Making Page 1 Establishing Rules for: Medical Device Reports (803) & Correction and Removal Reports.

Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.

U.S. Food and Drug Administration Pacific Region Retail Food Seminar September 22 – 24, 2015 Helena, Montana Luis Solorzano Director, State Cooperatives.

Competency-Development Project 08-October MDIC 2 What is the Competency-Development Project? ‏ Purpose: The purpose of this project is to improve.

1 BIORESEARCH MONITORING AND IN VITRO DIAGNOSTICS SYBIL WELLSTOOD, PH.D. OFFICE OF COMPLIANCE DIVISION OF BIORESEARCH MONITORING.

Enforcement Litigation and Compliance Washington, DC December 9-10, 2015 Compliance Central with FDA Center Compliance Directors (Part I) Michael Roosevelt,

Enforcement Litigation and Compliance Washington, DC December 9-10, 2015 ORA and FDA District Directors Forum Randy Pack, Director, Compliance Branch,

Update: Medical Device User Fee and Modernization Act of 2002 Blood Products Advisory Committee March 13, 2003 Mary Elizabeth Jacobs, Ph.D. Associate Director.

FDA job description  Regulates about 25% of all consumer purchases  Mission summary: protect and advance public health  Products: food, cosmetics, drugs,

Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Complaint and recall 1. Title 21--food and drugs Chapter I- food and drug administration department of health and human services Subchapter A- General.

FDA Facility Evaluation Douglas Stearn Deputy Director for Policy and Analysis Office of Compliance Center for Drug Evaluation and Research.

Overview of Operational Components of Prior Notice November 6, 2003 Max Castillo Division of Import Operations and Policy Office of Regulatory Affairs.

Current MFRPS State Implementation Status February 3, :15 – 9:45 am Timothy Weigner Staff Director U.S. FDA Office of Regulatory Affairs, Office.

Maridalia Torres District Director San Juan District Office Office of Regulatory Affairs Food and Drug Administration San Juan District Update “Protecting.

Office of Food Safety and Recall Food Safety Investigation and Recall Presented by: Francis Lindsay, CFIA Technical Specialist Querétaro, México, October.

AFDO Educational Conference: FDA Quality Initiatives Ricky Rodriguez, Director FDA Dallas District Office Steve Silverman, Director CDRH Office of Compliance.

Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.

Compliance Update Allergenic Products Advisory Committee Meeting March 15, 2002 Teddi Lopez DCM/OCBQ Center for Biologics Evaluation and Research.

Device regulations USA Dr Phil Warner. USA Regulations MEDICAL DEVICES Food, Drug & Cosmetics Act Medical Device Amendments of 1976 (and other things)

FSMA TRAINING Industry Recall Readiness BEST PRACTICES.

Executive Director, Registrar Corp

INDIANA AGRICULTURE Grow With Us!.

DRAFT 5/19/2018 Steve Gardner Compliance Investigator

American Society for Quality Region 5 Quality Conference

SPL Implementation Working Group Leyla Rahjou-Esfandiary October 2016

Overview of FDA Food Inspections

FDA Resources and Meetings

Office of Regulatory Affairs Division of Southwest Imports

Timothy B. Cleary, Esq. Meredith Manning, Esq.

New England District Update

Presentation transcript:

New England District Update MassMEDIC Conference December 1, 2010 Waltham, MA

New Hires 11 Consumer Safety Officers 11 Consumer Safety Officers 5 Supervisory Consumer Safety Officers 5 Supervisory Consumer Safety Officers

New Hires Dara Corrigan Associate Commissioner for Regulatory Affairs

New Hires District Director District Director District Quality Manager District Quality Manager

Currently Investigations Investigations 11 SCSO 113 CSOs/CSIs

Currently Compliance Compliance 10 CO’s 1 FOI Specialist

Inventory 8745 establishments 8745 establishments 3021 device firms3021 device firms

Accomplishments 1355 Inspections 1355 Inspections 264 Device inspections264 Device inspections 20 Foreign inspections 20 Foreign inspections

Recalls FY Total 126 Total 67 Device67 Device 6 Class I 6 Class I 55 Class II 55 Class II 6 Class III 6 Class III

Compliance Actions 22 Warning Letters 22 Warning Letters 9 Device QSRs9 Device QSRs 2 Permanent Injunctions 2 Permanent Injunctions

Compliance Actions 133 lines of imported devices detained worth about $2 million133 lines of imported devices detained worth about $2 million 53 refusals of imported devices worth about $164,00053 refusals of imported devices worth about $164,000

Compliance Actions Import Alert "DETENTION WITHOUT PHYSICAL EXAMINATION OF PRODUCTS FROM FIRMS REFUSING FDA FOREIGN ESTABLISHMENT INSPECTION“Import Alert "DETENTION WITHOUT PHYSICAL EXAMINATION OF PRODUCTS FROM FIRMS REFUSING FDA FOREIGN ESTABLISHMENT INSPECTION“ it appears that articles were manufactured, processed, or packed under insanitary conditions for purposes of section 801(a)(1) of the act thus refuse admission it appears that articles were manufactured, processed, or packed under insanitary conditions for purposes of section 801(a)(1) of the act thus refuse admission

FY11 Device Workplan INSPECTIONAL TYPENWE-DO (domestic/foreign) ORA (domestic/foreign) QSR156/ / 353 PMA14 / 5168 / 52 BIMO21 / 2295/ 25 TOTAL191 / / 354

Commissioner’s Enforcement Initiatives August Implement a formal Warning Letter “close-out” process Implement a formal Warning Letter “close-out” process After FDA determines violations have been corrected notice will be posted on FDA websiteAfter FDA determines violations have been corrected notice will be posted on FDA website For WL issued after 9/1/09For WL issued after 9/1/09 Warning Letter “close-out” process Warning Letter “close-out” process Since 09/01/09 a total 26 WL have been issued, 11 close out letters sent, 3 of which were device related

FDA Track CDRH CDRH Total number of 510(k) decisions made during the monthTotal number of 510(k) decisions made during the month ORA ORA Total number of foreign food, drug and device inspections and their classifications per monthTotal number of foreign food, drug and device inspections and their classifications per month Number of highest risk domestic inspections in the month resulting in a classification of Official Action IndicatedNumber of highest risk domestic inspections in the month resulting in a classification of Official Action Indicated